Skip to main content

First clinical trial site to adopt Florence eConsent successfully registers 250 patients in 1 month

ATLANTA–(Business Wire)–The first research site to adopt Florence eConsent has successfully registered 250 patients after just 30 days of using the platform. Florence designed eConsent to speed up the consenting process for sites while giving patients a deeper understanding of the informed consent document. 

“If we want to give every patient access to clinical trials, we need to help clinical trial sites and investigators in every community digitize their workflows,” said Ryan Jones, CEO of Florence. “Our team led the charge in eliminating paper-based Investigator Site Files and turning these critical documents digital with eBinders. Then we eliminated manual sponsor and site workflows with SiteLink, and now we’re transforming informed participant consent by ensuring it’s no longer slow, manual, and paper-based.” 

Florence Healthcare’s eBinders is the highest-rated electronic Investigator Site File platform on G2 and is currently used by 12,000 investigator sites in 45 countries. Its SiteLink solution, which connects clinical trial sponsors to the eISF at study sites for remote start-up, monitoring, and site management, now facilitates more than 3.8 million remote monitoring actions per month.

“We worked with leading research institutes to build eConsent so we could achieve three things: make it easy to use for the participants, make it intuitive for the study site, and make it more efficient than paper consent,” said Andrea Bastek, Ph.D., Sr. Director of Innovation for Florence. “Seeing the speed at which we’ve reached these milestones and the product’s rapid adoption by research organizations, it’s clear we’ve hit the mark.”

With the COVID public health emergency, eConsent became more important as participants visited hospitals less frequently and needed remote ways to communicate with site teams. According to the 2022 State of the Clinical Trial Technology Industry report, which surveyed more than 190 research leaders, 88% of study sites plan to use some form of eConsent by the end of the year.

“When it comes to informed consent, participant comfort and understanding is our top priority,” said Mason McLellan. McLellan works at The Knight Cancer Institute’s Cancer Early Detection Advanced Research Center. “By implementing eConsent, we can enable the participant to review the information not only with us in the office, but also at home with others involved in their care.”

Increasing access to clinical trials continues to be a major initiative in research. Digitizing workflows like consent allows traditionally centralized sites to expand their operations to local community sites and physicians while maintaining oversight and patient safety. 

“eConsent gives us the ability to standardize, monitor, and coordinate the consenting process across a wide geographic area, allowing greater access for participants,” said McLellan.

Several Institutional Review Boards (IRBs) and major pharmaceutical sponsors have already approved Florence’s eConsent, and it’s in use at major academic medical centers, local community clinics, and hospital systems across the United States.

Learn more about Florence Healthcare’s eConsent platform through the product tour and eConsent FAQs on Florence’s website. 

Powered by Florence

Florence’s clinical trial software helps more than 10,000 research sites in 45 countries manage their documents, data, and workflows. The Florence platform also provides remote access so sponsors and CROs can collaborate with their sites around the world and reach more patients than ever before. Florence users now perform 3 million remote monitoring activities each month. To learn more, visit florencehc.com.

Contacts

Blake Adams
Florence Healthcare
blake.adams@florencehc.com